Insights

Why BioCryst Stock Lost Nearly 4% of Its Value Today

What happened
BioCryst Pharmaceuticals (NASDAQ: BCRX) had a Thursday to forget, at least as far as its stock was concerned. The company’s shares took an almost 4% tumble that day, due to first-quarter results that investors clearly considered inadequate.
So what
For the quarter, BioCryst booked $49.9 million in revenue, which was more than double the slightly over $19 million in the same period of 2021. Nearly all of the latest top-line figure derived from the company’s latest FDA-approved and commercialized product, hereditary angioedema (HAE) drug Orladeyo.
Image source: Getty Images.

Yet a 54% increase in research and development expenses, plus a roughly similar boost in selling, general, and administrative costs — new-ish drugs typically require higher marketing and advertising spend — kept profitability well in the red. BioCryst’s net loss sank to over $74 million ($0.40 per share), against first-quarter 2021’s $64 million-plus deficit.
It was a case of “close, but no cigar” for the biotech in terms of meeting analyst expectations. On average, prognosticators tracking BioCryst stock were anticipating nearly $51.4 million in revenue and a slightly narrower per-share net loss of $0.37.
Now what
BioCryst continues to have high hopes for Orladeyo, believing that it has the potential to be a blockbuster drug with a peak of $1 billion in sales. The company quoted its CEO Jon Stonehouse as saying that it is “excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers.” 
Despite that, its projection for the treatment’s net revenue is more subdued. BioCryst provided very selected guidance for full-year 2022 that forecast $250 million for that line item with Orladeyo. However, it’s also estimating operating expenses (exclusive of noncash stock compensation) to land at $440 million to $480 million.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

BioCryst Pharmaceuticals (NASDAQ: BCRX) had a Thursday to forget, at least as far as its stock was concerned. The company’s shares took an almost 4% tumble that day, due to first-quarter results that investors clearly considered inadequate.

So what

For the quarter, BioCryst booked $49.9 million in revenue, which was more than double the slightly over $19 million in the same period of 2021. Nearly all of the latest top-line figure derived from the company’s latest FDA-approved and commercialized product, hereditary angioedema (HAE) drug Orladeyo.

Image source: Getty Images.

Yet a 54% increase in research and development expenses, plus a roughly similar boost in selling, general, and administrative costs — new-ish drugs typically require higher marketing and advertising spend — kept profitability well in the red. BioCryst’s net loss sank to over $74 million ($0.40 per share), against first-quarter 2021’s $64 million-plus deficit.

It was a case of “close, but no cigar” for the biotech in terms of meeting analyst expectations. On average, prognosticators tracking BioCryst stock were anticipating nearly $51.4 million in revenue and a slightly narrower per-share net loss of $0.37.

Now what

BioCryst continues to have high hopes for Orladeyo, believing that it has the potential to be a blockbuster drug with a peak of $1 billion in sales. The company quoted its CEO Jon Stonehouse as saying that it is “excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers.” 

Despite that, its projection for the treatment’s net revenue is more subdued. BioCryst provided very selected guidance for full-year 2022 that forecast $250 million for that line item with Orladeyo. However, it’s also estimating operating expenses (exclusive of noncash stock compensation) to land at $440 million to $480 million.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!